What is the EVERY?
Based in San Francisco, The EVERY Company is a biotechnology enterprise dedicated to developing high-performance proteins that replicate the functional and nutritional properties of animal-derived ingredients. By utilizing advanced precision fermentation, the firm creates sustainable, animal-free alternatives that cater to the evolving demands of the global food industry. The company's market position is defined by its ability to bridge the gap between traditional food science and modern sustainability, offering manufacturers clean-label solutions without compromising on taste or texture. This strategic focus on food technology innovation has positioned the firm as a critical partner for major food brands seeking to reduce their environmental impact while maintaining product quality.
How much funding has the EVERY raised?
the EVERY has raised a total of $315.1M across 8 funding rounds:
Angel/Seed
$1.7M
Angel/Seed
$20M
Debt
$350K
Multiple Rounds
$238M
Series D
$55M
Angel/Seed (2015): $1.7M, investors not publicly disclosed
Angel/Seed (2019): $20M, investors not publicly disclosed
Debt (2020): $350K supported by PPP
Debt (2021): $8M featuring Horizon Technology Finance Management LLC
Series A (2021): $15M, investors not publicly disclosed
Series B (2021): $40M, investors not publicly disclosed
Series C (2021): $175M led by Mcwin and RAGING CAPITAL MANAGEMENT
Series D (2025): $55M supported by Grosvenor, McWin Capital Partners, TO VC (to.vc, and Bloom8
Key Investors in the EVERY
McWin Capital Partners
McWin Capital Partners is a private investment firm that specializes in partnering with founders and CEOs to drive sustainable disruption in the food service and food technology sectors.
TO VC
TO VC is an early-stage venture capital fund that invests in innovative founders who are transforming energy production, food growth, infrastructure development, and climate change adaptation.
Bloom8
Bloom8 focuses on the FoodTech sector, investing in visionary founders who utilize disruptive technologies to improve food production and consumption.
What's next for the EVERY?
With the successful closure of this latest funding round, The EVERY Company is well-positioned to accelerate its commercialization efforts and deepen its research and development pipeline. The strategic focus will likely shift toward scaling manufacturing infrastructure to meet rising demand for its proprietary protein ingredients. Furthermore, the company is expected to leverage its partnerships with industry-leading investors to navigate complex regulatory landscapes and expand its presence in key international markets. As the alternative protein sector matures, the firm's ability to maintain its technological edge and operational efficiency will be paramount in securing long-term market dominance and driving the transition toward a more sustainable global food system.
See full the EVERY company page
